Search

258 Result(s)
Sort by

Dominik Huber

Dominik Huber

Dominik Huber, Our Head of Upstream Manufacturing in Vienna, Dominik Huber, has built his entire, senior-level career with Boehringer Ingelheim.
Nelli Milosch

Nelli Milosch

Nelli Milosch, a team lead for our field-based medical team in Germany, says that the people is the best thing about working in Boehringer Ingelheim.
Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes

Empagliflozin meets primary endpoint in reducing risk of cardiovascular death or hospitalization for heart failure in Phase III trial in adults with and without diabetes
Machine learning for patients

Machine learning for patients

Using AI to power patient-centric guideline optimization: discover the collaboration between Boehringer Ingelheim Canada, a community of cardiologists and Ensho Health.
ABILD

ABILD

ABILD partnership aims at enhancing health innovation projects to comprehend care gaps in diagnosis, treatment, and access for Albertans with progressive fibrosing ILD.
Pommeraie collaborative COPD strategy

Pommeraie collaborative COPD strategy

La Pommeraie's Collaborative COPD Strategy, with Boehringer Ingelheim Canada's Patient Access division, focuses on enhancing COPD patients' health and reducing hospitalizations.
Stefanie Bock Kreilinger

Stefanie Bock Kreilinger

Stefanie Bock-Kreilinger works in the legal department at Boehringer Ingelheim as head of corporate legal medicine, evidence and digital health.
ABIC Indigenous Populations

ABIC Indigenous Populations

Improving primary care in Alberta’s Indigenous Populations. Read more about ABIC, an example of how delivering innovative solutions can improve health equity.
Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction

Empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure by 25 per cent in adults with and without diabetes who had heart failure with reduced ejection fraction
JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® (empagliflozin) becomes the first and only approved treatment in Canada for adults with chronic heart failure regardless of ejection fraction

JARDIANCE® is the first and only heart failure therapy to demonstrate a statistically significant risk reduction in cardiovascular death and hospitalization for chronic heart failure1 Heart failure represents a significant, growing disease burden